Skip to content

IGM Biosciences

  • About Us
    • Our Company
    • Leadership Team
  • IGM Platform
    • Our IGM Platform
    • Publications
    • Presentations
  • Pipeline & Programs
    • Pipeline
    • Imvotamab
    • IGM-8444
    • IGM-7354
    • IGM-2644
  • Investors & News
  • Join Us
    • Our Culture
    • Open Jobs
  • Contact Us

Archives: Presentations

Presentations

Pharmacodynamics and Biomarker Correlates of Imvotamab (IGM-2323), the First-In-Class CD20xCD3 Bispecific IGM Antibody with Dual Mechanisms of Action, in Patients with Advanced B Cell Malignancies

64th American Society of Hematology (ASH) Annual Meeting and Exposition — December 10-13, 2022

IGM-2644, a Novel CD38xCD3 Bispecific IgM T Cell Engager Demonstrates Potent Efficacy on Myeloma Cells with an Improved Preclinical Safety Profile

64th American Society of Hematology (ASH) Annual Meeting and Exposition — December 10-13, 2022

CD123 Directed IgM T-cell Engager, IGM-2537, Demonstrates Potent in vitro and in vivo Activity with Minimal Cytokine Release

64th American Society of Hematology (ASH) Annual Meeting and Exposition — December 10-13, 2022

Unleashing the Power of Valency: A broad coverage, Receptor Trapping mechanism realized by the IgM platform for the prevention and treatment of infectious diseases

World Antiviral Congress — November 28-December 1, 2022

Dose Response Profile of IGM-2323, a CD20xCD3 IgM Bispecific T Cell Engager, in Translational Models Supports Phase 2 Dose Selection in Non-Hodgkin’s Lymphoma

European Hematology Association 2022 Hybrid Congress – June 9-12, 2022

 

A phase 1/2 randomized study of IGM-2323 in relapsed/refractory non-Hodgkin lymphomas

American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022

High valency of IGM-2323, a CD20xCD3 IgM bispecific T cell engager, displaces rituximab binding and induces potent B lymphoma cell killing

American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022

Enhanced NK and CD8+ T cell proliferation, tumor cytotoxicity and reversal of T cell exhaustion with IGM-7354, an anti-PD-L1 IgM antibody and IL-15 cytokine fusion

American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022

Anti-DR5 agonist IgM antibody IGM-8444 combined with SMAC mimetic birinapant induces strong synergistic tumor cytotoxicity

American Association for Cancer Research (AACR) Annual Meeting – April 8-13, 2022

A Phase 1 Dose Escalation Study of IGM-2323, a Novel Anti-CD20 x Anti-CD3 IgM T Cell Engager (TCE) in Patients with Advanced B-Cell Malignancies

63rd American Society of Hematology (ASH) Annual Meeting and Exposition – December 11-14, 2021 – Session: 623. Mantle Cell, Follicular, and Other B-Cell Lymphomas

Posts navigation

Older posts

All content © IGM Biosciences, Inc.    info@igmbio.com    Site Credits

LinkedIn